Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stem cell-mediated thymidine kinase gene therapy for glioblastoma
IRCT20200502047277N3Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jul 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ganciclovir in glioblastoma (GBM) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Overall survival and Progression-free survival. Started Jul 2019; status: completed.
02
Drugs
ganciclovir
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on IRCT20200502047277N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200502047277N3.